How should I manage an >80‑year‑old patient with hypernatremia, preserved ejection fraction, severe mitral regurgitation (MR), moderate tricuspid regurgitation (TR) and aortic regurgitation (AR), who is refusing oral fluids and had Lasix (furosemide) stopped?

Management of Hypernatremia in an Elderly Patient with Valvular Heart Disease and Refusal of Oral Intake

In this >80-year-old patient with sodium 154 mEq/L, preserved EF, severe valvular disease, and refusal of oral intake, you must immediately restart cautious IV diuresis while simultaneously addressing the hypernatremia with free water replacement—stopping Lasix was likely inappropriate given the severe valvular regurgitation and need for ongoing volume management.

Critical Assessment Framework

Volume Status Determination

This patient presents a complex clinical picture requiring careful assessment of their true volume state:

• Hypernatremia (Na 154) suggests hypovolemia from inadequate oral intake and recent diuretic discontinuation
• Severe MR, moderate TR and AR indicate chronic volume overload requiring ongoing diuretic therapy 1, 2
• The preserved EF of 58% does not eliminate the need for diuretic management in valvular heart disease

Key clinical signs to assess immediately:

• Jugular venous pressure (elevated suggests volume overload despite hypernatremia)
• Peripheral edema and ascites
• Pulmonary congestion on exam and chest X-ray
• Daily weights and urine output
• Orthostatic vital signs (if safe to obtain)
• Renal function and electrolytes 2, 3

The Diuretic Dilemma

Stopping Lasix was likely a mistake. The 2013 ACC/AHA guidelines are explicit: "Diuretics should be prescribed to all patients who have evidence of, and to most patients with a prior history of, fluid retention" 1. With severe MR and moderate TR/AR, this patient almost certainly has chronic volume overload requiring continuous diuretic therapy.

However, the hypernatremia creates a management challenge. The FDA label warns that "excessive diuresis may cause dehydration and blood volume reduction" and emphasizes monitoring for "hyponatremia, hypochloremic alkalosis, hypokalemia" 3. But hypernatremia is also a recognized complication requiring careful management.

Recommended Management Strategy

Immediate Actions (First 24 Hours)

1. Restart IV loop diuretics at reduced dose:

   • Begin IV furosemide at 20-40 mg once or twice daily (lower than typical starting doses) 1
   • The 2009 ACC/AHA guidelines specify that IV doses should "equal or exceed their chronic oral daily dose" in acute decompensation 2, but this patient's hypernatremia requires dose reduction
   • Monitor urine output hourly initially

2. Simultaneous free water replacement:

   • Provide IV D5W or hypotonic saline to correct hypernatremia
   • Target sodium reduction of 0.5 mEq/L per hour, maximum 10-12 mEq/L per 24 hours to avoid cerebral edema 4
   • Calculate free water deficit: 0.6 × body weight (kg) × [(Na/140) - 1]

3. Address refusal of oral intake:

   • Evaluate for reversible causes (nausea, depression, dysphagia, delirium)
   • Consider nasogastric tube if patient lacks capacity and has reversible condition
   • Involve palliative care if goals of care unclear in this elderly patient

Monitoring Protocol

Daily assessments must include 2, 5:

• Serum electrolytes, BUN, creatinine (initially twice daily given hypernatremia)
• Daily weights at same time
• Strict intake/output monitoring
• Volume status examination (JVP, edema, lung sounds)
• Blood pressure (supine and standing if safe)

The FDA label emphasizes that "serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of furosemide therapy" 3. In this acute setting, monitoring should be even more frequent.

Diuretic Titration Strategy

Once sodium normalizes (typically 48-72 hours):

• Increase IV furosemide dose gradually to achieve net negative fluid balance of 0.5-1.0 kg daily 1
• Target clinical euvolemia (resolution of edema, normal JVP, clear lungs)
• The 2009 guidelines state: "diuresis should be maintained until fluid retention is eliminated, even if this strategy results in mild or moderate decreases in blood pressure or renal function, as long as the patient remains asymptomatic" 2

If diuresis inadequate 2, 5:

• Increase loop diuretic dose (Class I recommendation)
• Consider adding thiazide (metolazone 2.5 mg once daily) for sequential nephron blockade 1
• Continuous infusion may be superior to bolus dosing 6

Special Considerations for Valvular Disease

The severe MR with moderate TR and AR creates unique challenges:

• These patients typically require higher diuretic doses long-term 7, 8
• Recent data shows loop diuretic dose ≥40 mg furosemide equivalent is associated with increased mortality in severe TR 7, but this reflects disease severity rather than diuretic harm
• The 2023 Canadian guidelines emphasize early GDMT optimization including diuretics for symptom control 9

Guideline-directed medical therapy should be optimized 9, 10:

• Consider SGLT2 inhibitor once stable (improves outcomes in HFpEF regardless of volume status)
• MRA (spironolactone 12.5-25 mg) if potassium permits
• These medications may reduce diuretic requirements over time

Critical Pitfalls to Avoid

1. Do not withhold diuretics solely due to hypernatremia in a patient with severe valvular regurgitation—this risks acute decompensation 1, 2

2. Avoid aggressive diuresis before correcting hypernatremia—this worsens hypovolemia and can precipitate renal failure 3

3. Do not correct sodium too rapidly (>12 mEq/L in 24 hours)—risk of osmotic demyelination syndrome 4

4. Monitor for diuretic-induced complications 3:

   • Hypokalemia and hypomagnesemia (can cause arrhythmias)
   • Worsening renal function (acceptable if mild and patient asymptomatic)
   • Hypotension (may require permissive approach 4)
   • Ototoxicity (rare but serious)

5. Recognize this may indicate end-stage disease—in an elderly patient refusing oral intake with severe valvular disease, consider goals of care discussion 11, 12

Prognosis and Long-term Planning

The combination of advanced age, severe valvular disease, and refusal of oral intake carries poor prognosis:

• Isolated severe TR has 17% 1-year mortality even with preserved LVEF 12
• High diuretic requirements (≥40 mg furosemide equivalent) predict worse outcomes 7, 13, 14
• Refusal of oral intake may indicate advanced frailty or depression requiring palliative care involvement

Surgical/interventional options are likely not feasible given age >80 and clinical status, but should be discussed with cardiology if patient stabilizes 15, 11.